OliX Pharmaceuticals, Inc (KOSDAQ:226950)

OliX Pharmaceuticals Balance Sheet

Financials in millions KRW. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	8,296	3,883	11,983	4,930	34,337	11,329
Short-Term Investments	-	-	10,000	53,000	15,000	55,000
Trading Asset Securities	3,240	8,531	3,942	3,941	420.68	1,782
Cash & Short-Term Investments	11,535	12,414	25,925	61,872	49,757	68,111
Cash Growth	-64.68%	-52.11%	-58.10%	24.35%	-26.95%	91.64%
Accounts Receivable	66.37	0	3,558	53.23	-	-
Other Receivables	853.49	907.84	1,419	996.88	272.13	159.18
Receivables	919.86	907.84	4,977	1,050	491.49	446.57
Inventory	542.89	554.26	468.41	657.17	374.13	304.17
Prepaid Expenses	1,087	1,370	244.9	1,367	1,480	7.13
Other Current Assets	1,211	287.98	526.86	99	136.92	178.26
Total Current Assets	15,296	15,534	32,142	65,046	52,240	69,047
Property, Plant & Equipment	50,832	51,385	43,910	37,232	31,525	6,180
Long-Term Investments	581.74	1,986	23,481	26,809	0.5	0.45
Other Intangible Assets	1,621	1,705	1,981	2,107	2,134	2,529
Other Long-Term Assets	633.52	639.62	1,312	1,458	772.05	820.53
Total Assets	68,965	71,249	102,825	132,651	86,672	78,577
Accrued Expenses	405.82	488.52	465.36	358.62	297.85	80.04
Short-Term Debt	1,320	13,441	-	-	-	-
Current Portion of Long-Term Debt	6,126	3,572	-	19,230	16,405	-
Current Portion of Leases	565.71	745.85	1,065	939.87	487.8	258.63
Current Income Taxes Payable	53.64	53.77	-	-	-	-
Other Current Liabilities	12,476	11,759	5,033	19,014	23,174	4,150
Total Current Liabilities	20,948	30,060	6,563	39,543	40,365	4,488
Long-Term Debt	20,536	21,428	35,362	20,000	20,326	14,011
Long-Term Leases	4.07	5.38	2,930	3,826	51.69	257
Long-Term Deferred Tax Liabilities	-	-	-	-	-	1,647
Other Long-Term Liabilities	944.32	867.98	7,634	3,080	6,296	12,597
Total Liabilities	42,995	52,777	52,489	66,449	67,265	33,227
Common Stock	9,888	9,230	8,010	6,852	6,852	6,771
Additional Paid-In Capital	197,397	175,533	157,177	151,895	92,908	91,128
Retained Earnings	-188,157	-167,785	-122,910	-103,224	-84,303	-54,379
Comprehensive Income & Other	6,198	871.87	7,141	8,885	3,064	1,765
Total Common Equity	25,325	17,849	49,418	64,407	18,521	45,286
Minority Interest	645.06	623.76	481.45	295.16	886.27	65.31
Shareholders' Equity	25,970	18,473	50,336	66,203	19,407	45,351
Total Liabilities & Equity	68,965	71,249	102,825	132,651	86,672	78,577
Total Debt	28,551	39,192	39,357	43,996	37,271	14,527
Net Cash (Debt)	-17,016	-26,778	-13,433	17,876	12,487	53,584
Net Cash Growth	-	-	-	43.16%	-76.70%	51.72%
Net Cash Per Share	-977.01	-1589.86	-930.93	1304.50	912.36	4074.15
Filing Date Shares Outstanding	18.71	18.46	16.02	13.7	13.7	13.54
Total Common Shares Outstanding	18.71	18.46	16.02	13.7	13.7	13.54
Working Capital	-5,652	-14,526	25,578	25,502	11,874	64,559
Book Value Per Share	1353.57	966.92	3084.79	4700.19	1351.59	3344.07
Tangible Book Value	23,704	16,144	47,437	62,300	16,387	42,756
Tangible Book Value Per Share	1266.92	874.55	2961.16	4546.39	1195.84	3157.30
Land	25,460	25,460	25,740	25,740	25,740	988.21
Buildings	23,033	23,033	3,354	3,354	3,354	3,115
Machinery	7,435	7,425	6,436	5,518	4,427	3,330
Construction In Progress	-	-	8,948	1,239	71.73	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.